Dantrolene: Difference between revisions
(Created page with "==Administration== *Type: Skeletal muscle relaxant *Dosage Forms: *Routes of Administration: *Common Trade Names: ==Adult Dosing== ===Neuroleptic malignant syndrome=== *...") |
ClaireLewis (talk | contribs) |
||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 2: | Line 2: | ||
*Type: Skeletal muscle relaxant | *Type: Skeletal muscle relaxant | ||
*Dosage Forms: | *Dosage Forms: | ||
*Routes of Administration: | *Routes of Administration: IV, oral | ||
*Common Trade Names: | *Common Trade Names: Dantrium | ||
==Adult Dosing== | ==Adult Dosing== | ||
| Line 11: | Line 11: | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
*Same as above | |||
==Special Populations== | ==Special Populations== | ||
*[[Drug pregnancy categories|Pregnancy Rating]]: | *[[Drug pregnancy categories|Pregnancy Rating]]: C | ||
*Lactation risk: | *Lactation risk: Infant risk cannot be ruled out | ||
*Renal dosing: no adjustment | |||
*Hepatic dosing: contraindicated in acute hepatitis or active cirrhosis | |||
* | |||
==Contraindications== | ==Contraindications== | ||
*Allergy to class/drug | *Allergy to class/drug | ||
*Acute hepatitis or active cirrhosis | |||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
* | *Hepatotoxicity | ||
*GI bleed | |||
*Aplastic anemia, leukopenia, thrombocytopenia, small lymphocytic lymphoma | |||
*Muscle weakness, dysphagia, reduced vital capacity, dyspnea | |||
===Common=== | ===Common=== | ||
*Flushing | |||
*Somnolence, fatigue, malaise | |||
*Nausea, diarrhea | |||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: 10.8h | ||
*Metabolism: | *Metabolism: Hepatic | ||
*Excretion: | *Excretion: | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
*Interferes with release of calcium ions from sarcoplasmic reticulum in skeletal muscle, which results in dissociation of the excitation-contraction coupling | |||
==Comments== | ==Comments== | ||
| Line 45: | Line 46: | ||
==See Also== | ==See Also== | ||
*[[Neuroleptic malignant syndrome]] | |||
==References== | ==References== | ||
| Line 51: | Line 52: | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:Toxicology]] | |||
Latest revision as of 23:49, 20 September 2019
Administration
- Type: Skeletal muscle relaxant
- Dosage Forms:
- Routes of Administration: IV, oral
- Common Trade Names: Dantrium
Adult Dosing
Neuroleptic malignant syndrome
- 0.25-2mg/kg IV q6-12hr
- Max dose 10mg/kg/day
Pediatric Dosing
- Same as above
Special Populations
- Pregnancy Rating: C
- Lactation risk: Infant risk cannot be ruled out
- Renal dosing: no adjustment
- Hepatic dosing: contraindicated in acute hepatitis or active cirrhosis
Contraindications
- Allergy to class/drug
- Acute hepatitis or active cirrhosis
Adverse Reactions
Serious
- Hepatotoxicity
- GI bleed
- Aplastic anemia, leukopenia, thrombocytopenia, small lymphocytic lymphoma
- Muscle weakness, dysphagia, reduced vital capacity, dyspnea
Common
- Flushing
- Somnolence, fatigue, malaise
- Nausea, diarrhea
Pharmacology
- Half-life: 10.8h
- Metabolism: Hepatic
- Excretion:
Mechanism of Action
- Interferes with release of calcium ions from sarcoplasmic reticulum in skeletal muscle, which results in dissociation of the excitation-contraction coupling